U.S. scientists have reported meaningful results from clinical trials of a new rapid-acting antidepressant. Mechanism of action on the central nervous system like ketamine, but without apparent effects noted during its use. The work was published in Biological Psychiatry.
All currently known antidepressants contribute by different mechanisms increased levels in the CNS neurotransmitters such as noradrenaline, serotonin, dopamine and others. The main disadvantage of these drugs is their deferred action, which is very important for patients with severe major depressive disorder. Anesthetic ketamine and psychoactive drug belonging to the class NMDA-receptor antagonist, is effective for a few hours, as an antidepressant is never used since the occurrence of side effects - occurrence dissociative disorders (hallucinations and splitting of consciousness).
Antidepressant AZD6765R created by a group of experts working under the auspices of the National Institute of Mental Health United States, like ketamine, inactivates the receptor NMDA, which from neuron to neuron transmits electrical signals in the brain and spinal cord, the neurotransmitter glutamate, thus reducing its undesirable toxic effects of depression . However, the effectiveness of the new substance is somewhat weaker than that of ketamine.
Ispytynie AZD6765 was conducted on 22 patients with persistent major depressive disorder. None of the known antidepressants did not facilitate the condition of these people, and half of them are even electroconvulsive therapy has not acted. One group of participants was done twice, with an interval of a week injection of 150 mg of AZD6765, the other participants - placebo. After that depressive symptoms were assessed by experts on the scale of the Montgomery-Asberg first one hour, 80 minutes, 110 minutes, 230 minutes after the injection, and then every other day, two, three a week.
In 32% of patients who received an injection of AZD6765, was observed after only 80 minutes of a reference in the body of the drug clinically significant improvement in contrast to the participants who took the placebo. This is a significant improvement only lasted half an hour, but the residual effect of the antidepressant was marked them for two more days. Hallucinogenic and dissociative action with AZD6765 was observed. This is a very good results, according to researchers, given the stability of the patients who participated in the trial.
The authors intend to continue clinical trials of AZD6765 in order to ensure that will not give rise to the frequency of injection or increase their doses over a long-term effect.